David Smadja/Wikipedia
Jun 7, 2025, 08:46
David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
David Smadja, Team Director “Endotheliopathy and hemostasis disorders” at INSERM The Paris Cardiovascular Research Center, shared a post on LinkedIn:
“A major step forward in the fight against cancer-related thrombosis!
In the journal VAINCRE LE CANCER – NRB, we take a look back at the API-CAT study, led by Prof. Isabelle Mahé (Louis Mourier Hospital AP-HP) and our team at PARCC – Inserm Endotheliopathy & Hemostasis Disorders.
Result? A reduced dose of apixaban is sufficient to prevent thromboembolic recurrence with less bleeding.
This is further proof that academic research is changing clinical practices. Proud to contribute to this breakthrough in the service of cancer patients.”
You can read a wide variety of new scientific posts in Hemostasis Today.
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases
-
Feb 24, 2026, 15:30Aswin K Mohan: Practical Tips for Preparing Before, During, and After Blood Donation
-
Feb 24, 2026, 15:24Stéphanie Forté: The Hidden Burden of Stroke in Adults Living with Sickle Cell Disease
-
Feb 24, 2026, 15:13Tagreed Alkaltham: Equity in Emergency Care Through a Blood Bank Lens
-
Feb 24, 2026, 14:57Joseph Raffaele: Can Improving Mitochondrial Quality in Immune Cells Alter Immune Aging Markers?